Global $49.3+ Artificial Intelligence (AI) in Biopharmaceuticals Market Report 2023-2033: Surge in Collaborations Among Organizations for Drug Development Enabled by AI - ResearchAndMarkets.com

The "Artificial Intelligence (AI) in Biopharmaceuticals Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.

The report forecasts strong revenue growth in the market, with the overall world revenue surpassing US$49.3 billion in 2023. The study identifies organizations with the greatest potential in the field, outlining their capabilities, progress, and commercial prospects.

Key Market Drivers

• Automation in Drug Discovery and Development: AI technologies enable automation in drug discovery and development processes, leading to more efficient and cost-effective research and development.
• Better Data Analysis and Pattern Recognition: AI's ability to analyze vast amounts of data and recognize patterns in biopharma accelerates technology adoption in the industry.
• Patent Expiry: AI-driven development provides opportunities for companies to innovate and develop new drugs as existing patents expire.

Market Restraints

• Developing Interoperability Systems: Establishing connectivity and communication between devices and IT systems, as well as between data and workflows, poses a challenge for the biopharmaceutical industry.
• Data Privacy and Security: Concerns over data privacy and security may hinder the adoption of AI in biopharmaceuticals.

Market Opportunities

• Increasing Collaborations: Collaborations among organizations for drug development enabled by AI are on the rise, leading to advancements in precision medicine and therapies for various conditions.
• Lucrative Investment in India: India is identified as one of the most lucrative countries for investment in biotechnologies, presenting opportunities for AI-driven advancements.

Key Questions Addressed by the Report

The report helps companies understand the evolving AI in the biopharmaceutical market and the factors driving and restraining its growth. It provides revenue forecasts for submarkets and identifies the main drivers for the overall market from 2023 to 2033. The report also assesses whether leading AI in biopharmaceutical markets will follow macroeconomic dynamics or if individual national markets will outperform others.

Additionally, the report includes revenue forecasts for five regional and 17 leading national markets, making it valuable for companies looking to expand their operations into different regions.

Segments Covered in the Report

The report segments the AI in biopharmaceutical market based on technology, application, and end-users. Technology segments include Deep Learning, NLP, Image Processing, and Other Technologies. Application segments cover Business Process & Supply Chain, Drug Discovery, Medical Imaging & Diagnostics, and Precision Medicine. End-users are categorized into Manufacturers, Contract Research Organizations, and Academic & Government Research Institutes.

Market Dynamics

The report delves into market dynamics, including the factors driving and restraining the AI in biopharmaceutical market. It highlights automation in drug discovery and development, better data analysis with AI, and opportunities arising from patent expiry. The challenges of developing interoperability systems and concerns about data privacy and security are also discussed.

Leading Players

Profiles of leading companies in the AI in the biopharmaceutical market are included, providing insights into their operations and prospects over the forecast period (2023-2033).

Leading Companies and the potential for market growth

• Alphabet Inc.
• Amgen Inc.
• ConcertAI
• Exscientia
• Insilico Medicine
• Merative (IBM)
• Microsoft
• NVIDIA Corporation
• Schrodinger, Inc.
• Tencent
• AIBrain
• Almirall
• Amazon
• Apple
• AstraZeneca
• Atomwise
• Babylon Health
• Bayer
• Bio-Manguinhos
• Bio-Rio
• Biotecnol
• BioXcel Therapeutics
• BrainOS
• Bristol-Myers Squibb
• Cleveland Clinic
• Collaborations Pharmaceuticals, Inc.
• Deep 6 AI
• DeepL
• DeepMind Health
• Deepomatic
• Ferrer
• Generate Biomedicine
• GlaxoSmithKline
• Grifols
• MediChain
• Merck & Co.
• Novartis
• Novo Nordisk A/S
• NuMedii
• Otsuka Pharmaceutical Development & Commercialization, Inc.
• Oxford Nanopore
• PubMed
• Sanofi
• Siemens Healthineers
• Snips
• Teva Pharmaceuticals
• Usynova
• VinBrain
• Ayushman Bharat Digital Mission (ABDM)
• Ayushman Bharat Health Account (ABHA)
• Imperial College London
• Ministry of Health, Labor and Welfare (MHLW)
• National Autonomous University of Mexico (UNAM)
• National Health Authority (NHA)
• National Health System (SNS)
• National Institute for Health Research (NIHR)
• National Institute of Biotechnology and Applied Sciences (INBIOTEC)
• National Institute of Health Carlos III (ISCIII)
• National Institutes of Health (NIH)
• NC State University
• Organisation for Economic Co-operation and Development (OECD)
• South African National Bioinformatics Institute (SANBI)
• United States Department of Health and Human Services
• University of Oxford
• University of the Witwatersrand (Wits)

   

   

For more information about this report visit https://www.researchandmarkets.com/r/dslhab

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230816811010/en/